
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is well-positioned within the medical device industry for future growth with its innovative portfolio of products targeting surgical treatments for various cardiac conditions, including atrial fibrillation and left atrial appendage management. The company's strong financial results in the fourth quarter of 2025, with increased revenue and significant margin expansion, demonstrate its potential for sustained revenue growth and improvement in profitability. The recent success of AtriCure's clinical trials and the continued adoption of its products by physicians also support a positive outlook for the company's performance in the coming years.
Bears say
AtriCure is facing continued pressure in international markets, particularly in Germany and UK, and the company has already incorporated this into their revised 2026 outlook. However, with the potential success of their BOxX-NoAF trial and the high healthcare costs associated with post-operative Afib, there is still potential for long-term growth for AtriCure. Additionally, the company's diverse product line and focus on pain management may help to offset any short-term sales declines.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares